Chemical Week Magazine :: Business & Finance :: United States/Americas
GSK to license Codexis technology
6:51 AM MDT | July 18, 2014 | —Rebecca Coons
Biocatalyst firm Codexis (Redwood City, CA) and GlaxoSmithKline (GSK) have announced a technology license agreement worth up to $25 million in initial payments and milestone and royalty opportunities to Codexis. Under the terms of the deal, Codexis licenses GSK to use Codexis’s proprietary CodeEvolver protein engineering platform technology in human health care. The agreement allows GSK to use the technology to develop novel enzymes for manufacturing GSK’s pharmaceutical and health-care products. Upon completion of technology transfer, GSK will have...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee